Skip to main content

Table 3 Antimicrobial resistance profiles of CTX-M-producing Escherichia coli according to locations of acquisition and CTX-M types

From: Molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli in the community and hospital in Korea: emergence of ST131 producing CTX-M-15

Antimicrobial agent Total (n = 139) Hospital-onset (n = 60) Community-onset CTX-M type   
    Total (n = 79) Healthcare-associated (n = 46) Community-associated (n = 33) CTX-M-14 (n = 69) CTX-M-15 (n = 53) CTX M-14 + M-15 (n = 17)
Amikacin 14 (10.1) 7 (11.7) 7 (8.9) 3 (6.5) 4 (12.1) 4 (5.8) 7 (13.2) 3 (17.6)
Gentamicin 92 (65.5) 45 (73.8) a 47 (59.5) 28 (60.9) 19 (57.6) 37 (53.6) 40 (75.5)b 15 (88.2)b
Tobramycin 94 (67.6) 46 (76.7) 48 (60.8) 29 (63.0) 19 (57.6) 36 (52.2) 43 (81.1)b 15 (88.2) b
Aztreonam 130 (93.5) 60 (100) 70 (88.6) 43 (93.5) 27 (81.8) 62 (89.9) 51 (96.2) 17 (100)
Cefepime 132 (95.0) 58 (96.7) 74 (93.7) 44 (95.7) 30 (90.9) 65 (94.2) 51 (96.2) 16 (94.1)
Ceftazidime 77 (55.4) 38 (63.9) 39 (49.4) 24 (52.2) 15 (45.5) 20 (29.0) 43 (81.1)b 14 (82.4) b
Cefotaxime 139 (100) 60 (100) 78 (100) 46 (100) 32 (100) 69 (100) 52 (100) 17 (100)
Ciprofloxacin 105 (75.5) 52 (86.7) a 53 (67.1) 34 (73.9) 19 (57.6) 47 (68.1) 42 (79.2) 16 (94.1)b
Piperacillin-tazobactam 33 (23.7) 20 (33.3) a 13 (16.5) 7 (15.2) 6 (18.2) 11 (15.9) 10 (18.9) 12 (70.6) b,c
Trimethoprim-sulfamethoxazole 89 (64.0) 38 (63.3) 51 (64.6) 29 (63.0) 22 (66.7) 52 (75.3) 31 (58.5) b 6 (35.3) b
Multidrug resistance 120 (86.3) 53 (88.4) 67 (84.8) 39 (84.8) 28 (84.8) 55 (79.7) 48 (90.6) 17 (100)b
Resistance scored ≥ 3 71 (51.1) 39 (65.0) a 32 (40.5) 19 (41.3) 13 (39.4) 26 (37.7) 31 (58.5) b 14 (82.4) b
  1. a For comparison with CO isolates, P < 0.05.
  2. b For comparison with CTX-M-14 producing isolates, P < 0.05.
  3. c For comparison with CTX-M-15 producing isolates, P < 0.001.
  4. d Number of antimicrobial classes, apart from penicillin and cephalosporin, to which E. coli isolates are non-susceptible.